BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, April 20, 2025
Breaking News: Trump administration impacts
See today's BioWorld Science
Home
» NN-42-1007: First potent and selective hepatic glycogen phosphorylase inhibitor
To read the full story,
subscribe
or
sign in
.
NN-42-1007: First potent and selective hepatic glycogen phosphorylase inhibitor
June 7, 1996
BioWorld Science
Conferences
New compound
Endocrine/metabolic
